GlaxoSmithKline has no plans to delist Indian arm - exec

MUMBAI Mon Nov 26, 2012 11:13am IST

Related Topics

Stocks

   

MUMBAI (Reuters) - GlaxoSmithKline Plc (GSK.L) has no plans to delist its Indian consumer products arm GlaxoSmithKline Consumer Healthcare Ltd (GLSM.NS), David Redfern, chief strategy officer at Britain's biggest drugmaker, said on Monday.

GSK said earlier it planned to buy up to an additional 31.8 percent stake in the Indian unit for 52.2 billion rupees.

The company has been expanding into both emerging markets and non-prescription consumer health - and in some cases a combination of the two.

The company, which plans to launch new variants of the flagship Horlicks brand in India, is looking to increase penetration of the product in the north and western regions of the country, Redfern said. (Reporting by Kaustubh Kulkarni; Editing by Subhranshu Sahu)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Jaitley's Health

Jaitley's Health

Finance minister back in hospital for check-up.  Full Article 

Modi's U.S. Visit

Modi's U.S. Visit

Modi to observe strict fast during maiden trip to U.S.  Full Article 

Mangalyaan

Mangalyaan

India's Mars mission a step closer to success with engine test  Full Article 

Shortage of Coal

Shortage of Coal

Coal import rush leads to port congestion  Full Article 

Alibaba IPO

Alibaba IPO

IPO ranks as world's biggest after additional shares sold   Full Article 

Bumper Sales

Bumper Sales

Apple sells more than 10 mln new iPhones in first three days  Full Article 

Asian Games 2014

Asian Games 2014

Full coverage of the 17th Asian Games as Incheon.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage